Total Knee Replacement Clinical Trial
— Yale SEVENOfficial title:
Yale Steroid Enhanced Versus Exparel Nerveblock TKA Randomized Controlled Trial (RCT) Study
The objective of this phase 2 study is to investigate the efficacy of Dexamethasone sodium phosphate (DEX) plus Methylprednisolone acetate (MPA) in combination with plain bupivacaine (B) compared with Liposomal Bupivacaine (LB) in combination with plain bupivacaine on post-surgical pain control among patients undergoing unilateral total knee arthroplasty (TKA) to asses if perineural B-DEX-MPA will result in superior analgesia efficacy as compared to B-LB. This study will also assess if perineural B-DEX-MPA results in improved quality of postoperative recovery as compared to B-LB.
Status | Recruiting |
Enrollment | 250 |
Est. completion date | March 2026 |
Est. primary completion date | March 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - American Society of Anesthesiologists status I, II and III, elective, primary, unilateral TKA planned for spinal anesthesia with plain 0.5% bupivacaine. Exclusion Criteria: - Refusal of consent - Pregnancy - Conditions making the patient unable to fill out questionnaire online, through email or over the phone including with cognitive dysfunction, psychiatric disorder, or non-English speaking patients, or lack of internet access which would prevent post discharge follow-up electronically - Coagulopathy - Allergy to or for any other reasons cannot use Acetaminophen, Celebrex, local anesthetic bupivacaine, DEX, MPA or LB - Patients on any amounts of opioids within one month of the surgery date, any substance abuse such as regular marijuana user (more frequent than once per month) - Insulin dependent or uncontrolled diabetes defined as, day of surgery finger stick glucose >200mg/dl, or HbA1C > 8.0% - Peripheral Nerve Block site or systemic infection - Immune compromise (e.g., HIV, chronic glucocorticoid use) - Severe pre-existing neuropathy - TKA for indications other than osteoarthritis such as post-traumatic injury or rheumatoid arthritis, history of surgery in the ipsilateral knee joint, revision TKA or bilateral TKA - Severe hepatic or renal dysfunction (GFR <50 ml/min) - Actual body weight <60 kg - Patients with active or latent peptic ulcers, diverticulitis, fresh intestinal anastomoses, and non-specific ulcerative colitis |
Country | Name | City | State |
---|---|---|---|
United States | Yale New Haven Hospital Saint Raphael Campus | New Haven | Connecticut |
United States | Yale New Haven Hospital York Street Campus | New Haven | Connecticut |
Lead Sponsor | Collaborator |
---|---|
Yale University | Department of Anesthesiology Faculty Development Fund |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Postoperative Knee Pain Score | Average postoperative knee pain scores for the first two postoperative days using Visual analogue scale (VAS) pain score. Score range from 0 (no pain) to 10 (worst pain possible). | Day 1 and Day 2 | |
Primary | Postoperative opioid consumption | In-hospital postoperative opioid consumption in oral milligram morphine equivalent (OME) will be monitored up to 48-hour between anesthesia end time and discharge time | From anesthesia end time to discharge time, up to 48 hours | |
Secondary | Average Postoperative Knee Pain Score | Average postoperative knee pain scores for postoperative day 7 using Visual analogue scale (VAS) pain score. Score range from 0 (no pain) to 10 (worst pain possible). | Day 7 | |
Secondary | Worst and best pain score | Worst and best postoperative knee pain scores for days 1, 2 and 7 using Visual analogue scale (VAS) pain score. Score range from 0 (no pain) to 10 (worst pain possible). | Day 1, Day 2 and Day 7 | |
Secondary | Change in functional pain using Brief Pain Inventory (BPI) | Compare functional pain using the BPI at baseline, 6 weeks and 3 months. The BPI scale defines pain as follows: Score: 1 - 4 = Mild Pain, Score: 5 - 6 = Moderate Pain, Score: 7 - 10 = Severe Pain. | baseline, 6 weeks and 3 months | |
Secondary | Change in neuropathic pain using PainDetect | Compare neuropathic pain at baseline, 6 weeks and 3 months using PainDetect: a nine-item questionnaire that consists of seven sensory symptom items for pain that are graded from 0= never to 5= strongly, one temporal item on pain-course pattern graded -1 to +1, and one spatial item on pain radiation graded 0 for no radiation or +2 for radiating pain. | baseline, 6 weeks and 3 months | |
Secondary | Persistent opioid use using Yale Postoperative Recovery Scale | Persistent opioid use will be compared using the Yale Postoperative Recovery Scale on postoperative day 7, 6 weeks and 3 months. It is comprised of 3 free-text questions: Is patient still taking opioid medications, Yes or No; The number of pills left in pill box;and Has the patient needed a prescription refill, Yes or No. | Day 7, 6 weeks and 3 months | |
Secondary | Persistent opioid use using NarX | Persistent opioid use will be compared using the NarX score at 6 weeks and 3 months, scores range from 000-999; higher scores indicate more opioid usage | 6 weeks and 3 months | |
Secondary | Change in Quality of Recovery 40 questionnaire | 40 questions assessing quality of recovery graded on a five-point Likert scale, total score range from 40 (extremely poor recovery) to 200 (excellent recovery) | Day 1, 2 and 7 | |
Secondary | Prosthetic joint range of motion | Compare prosthetic joint range of motion using the patient's electronic medical record as reported by the physical therapist at baseline, day 0, day 1, and day 2 | baseline, day 0, day 1 and day 2 | |
Secondary | Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Global-10 | The PROMIS Global-10 is a 10-item patient-reported questionnaire that measures changes in general health in which the response options are presented as 5-point scale, 5 (without any difficulty) to 1 (Unable to do). Higher scores indicate a healthier patient. | 6 weeks and 3 months | |
Secondary | Change in knee functional status using Knee injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS JR) | Compare knee functional status using KOOS JR at 6 weeks and 3 months after surgery, Scores range from 0 to 100 with a score of 0 indicating total knee disability and 100 indicating perfect knee health. | 6 weeks and 3 months | |
Secondary | Length of stay | The patient's post surgical length of stay in the hospital will be compared between treatment groups. | from the start of the surgery to discharge from hospital, up to 48 hours | |
Secondary | Change in glucose | Compare the change in postoperative serum glucose from baseline only for participants that have an overnight hospital stay | baseline, day 0, day 1 and day 2 | |
Secondary | Change in white blood cell count (WBC) | Compare the change in postoperative WBC from baseline only for participants that have an overnight hospital stay | baseline, day 0, day 1 and day 2 | |
Secondary | Absolute value of Interleukin 1 beta (IL-1b) | Absolute value IL-1b at postoperative day 1 only for participants that have an overnight hospital stay | day 1 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04040985 -
Legion Primary Safety and Efficacy
|
N/A | |
Completed |
NCT03286543 -
Electrical Stimulation for the Treatment of Pain Following Total Knee Arthroplasty Using the SPRINT Beta System
|
N/A | |
Not yet recruiting |
NCT04594447 -
Physica System KR vs Physica System CR (K-20)
|
N/A | |
Completed |
NCT02413996 -
Effects of Virtual Reality Rehabilitation in Patients With Total Knee Arthroplasty
|
N/A | |
Completed |
NCT01500252 -
Patellar Resurfacing Versus Patellar Retention in Total Knee Arthroplasty - A Randomized Clinical Trial
|
Phase 4 | |
Completed |
NCT04081493 -
The Efficacy of Low-load Blood Flow Restricted Resistance Before TKR
|
N/A | |
Active, not recruiting |
NCT03339557 -
Comparison of Three Knee Replacements
|
N/A | |
Enrolling by invitation |
NCT04513145 -
Adductor Canal Block
|
Phase 2/Phase 3 | |
Completed |
NCT06045078 -
Aromatherapy in Total Knee Replacement
|
N/A | |
Completed |
NCT02468934 -
Electrical Stimulation for the Treatment of Pain Following Total Knee Arthroplasty (TKA) Using the SPRINT System
|
N/A | |
Completed |
NCT02914210 -
Virtual vs. Traditional Physical Therapy Following Total Knee Replacement
|
N/A | |
Withdrawn |
NCT01523418 -
Study to Observe Safety of Xarelto in VTE Prophlylaxis After Elective TKR (Total Knee Replacement) or THR (Total Hip Replacement)
|
N/A | |
Completed |
NCT00795223 -
Comparative Pain Control Between 0.2 or 0.3 Spinal Morphine and 0.25 or 0.5 % Bupivacaine for FNB After TKA
|
Phase 4 | |
Completed |
NCT01307202 -
Morphine Consumption in Joint Replacement Patients, With or Without Gabapentin Treatment
|
N/A | |
Completed |
NCT01515449 -
Predictors of Poor Outcomes in 1038 Sigma Knees
|
N/A | |
Completed |
NCT01522781 -
10 Year Outcome of Total Knee Replacement (TKR) Using Sigma Prosthesis
|
N/A | |
Completed |
NCT04166539 -
Neurotoxicity and Cardiotoxicity in Total Joint Arthroplasty
|
||
Completed |
NCT03454256 -
Virtual Reality Rehabilitation in Patients With Total Knee Replacement
|
N/A | |
Enrolling by invitation |
NCT06118073 -
Effect of Mindfulness on Pain After Total Knee Arthroplasty
|
N/A | |
Completed |
NCT05597046 -
Qualitative Interviews With Healthcare Professionals
|